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FIGURE 1. Mortality (per 1000 people) from lung cancer in men and women in the US according to
age and smoking status.4
LETTERS TO THE EDITORSCREENING WITH LOW-DOSE
COMPUTED TOMOGRAPHY:
RESPONSE TO THE AMERICAN
ASSOCIATION OF
THORACIC SURGERY
GUIDELINES
To the Editor:
In the recently published American
Association for Thoracic Surgery
(AATS) guidelines for lung cancer
screening,1 it was recommended that
computed tomographic (CT) screen-
ing should include current and former
smokers of wider eligibility than that
recently recommended by Bach and
colleagues2 on the basis of the Na-
tional Lung Screening Trial (ages
55-74 years, 30 pack-year, quit
time<15 years). Such a recommenda-
tion recognizes that the National Lung
Screening Trial criteria have poor
sensitivity (estimated to be <50%)
relating to their exclusion of many
high-risk smokers who fall outside
these criteria.3 We strongly endorse
the broader eligibility criteria for CT
screening and outline here why this
broadening is justified.
First, as outlined in theAATSguide-
lines,1 the age-specific incidence of
lung cancer goes up beyond 75 years
of age. More importantly, age-
specific lung cancer mortality in the
US (accounting for competing causes
of death) increases exponentially after
50 years of age and peaks at 80 years of
age (Figure 1).4 These data further sup-
port the widening of the eligibility cri-
teria to include those 50 to 79 years
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The Journalthe age criteria1 will increase the pro-
portion of lung cancer cases eligible
for screening by an estimated 10% to
15% (47% with National Lung
Screening Trial–based recommenda-
tions and 62%with AATS recommen-
dations).3 Similarly, we estimate
a widening of the pack-year smoking
history (to include 20-29 pack-year)
will add a further 10% to 15% of
lung cancer cases. We therefore agree
with the AATS recommendation1 to
screen current or former smokers
with wider age and pack year criteria
(50-79 years and 20 pack-year)
with additional risk factors. We sug-
gest that both chronic obstructive
pulmonary disease and a genetic
predisposition are particularly rele-
vant, becausewe have found that these
risk variables confer 4- to 6-fold and
2- to 10-fold increased risks of lung
cancer, respectively, relative to the
risk derived from age and smoking
history alone.5
Although we agree that clinically
validated lung cancer risk tools should
be used in CT screening selection, we
are less convinced that web-based re-
porting of absolute risk (http://www.
mskcc.org/cancer-care/adult/lung/preof Thoracic and Cardiovascular Surgediction-tools) is the best way to iden-
tify and engage smokers for CT screen-
ing.1 First, this is because risk reported
as an absolute risk is a concept poorly
understood by doctors and patients
alike. It is well documented that for ab-
solute risk to be understood, it needs to
be compared with the risks of other
people or different circumstances (as
illustrated by Jaklitsch and col-
leagues1), thereby converting absolute
risk into a comparative or relative
risk.4,5 Second, comparative risk is an
important concept in promoting risk
mitigating actions such as smoking
cessation,4 considered an integral part
of CT screening in all recommended
guidelines to date.1,2 We have
recently demonstrated that a gene-
based risk tool that we developed for
lung cancer risk improves both smok-
ing cessation and interest in CT screen-
ing,6 most likely through increasing
motivational tension and undermining
the unrealistic optimism commonly
seen in smokers. We conclude that
wider eligibility criteria for CT screen-
ing are justified and that patient-
friendly risk assessment can provide
a teachable moment with which to tar-
get and engage high-risk smokers inry c Volume 145, Number 1 307
Letters to the Editorsuch risk-mitigating actions as CT
screening and smoking cessation.
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j.jtcvs.2012.08.074Reply to the Editor:
We thank Drs Young and Hopkins
for their kind remarks in favor of the
American Association for Thoracic
Surgery guidelines for lung cancer
screening with low-dose chest com-
puted tomographic scans. In creating
guidelines on the basis of a successful
research protocol, the Association
chose to expand the age of the screen-
ing population beyond the ages of the
participants in the National Lung
Screening Trial.1 The rationale behind
this decision included the age distribu-
tion of the disease in North America,
the fact that increasing age is an inde-
pendent risk factor for development of
cancer, and the improvement in308 The Journal of Thoracic and Cquality life years expected up to the
9th decade of life. Drs Young and
Hopkins offer additional justification
for this guideline, namely the age-
specific lung cancer mortality in the
United States increases exponentially
after the age of 50, with a peak at the
age of 80 years.
We envision a Web-based program
that would allow each citizen to cal-
culate his or her own absolute risk
of lung cancer, dissemination of eas-
ily updated educational materials,
and potential data collection for spe-
cific populations. It is our hope that
such risk assessment would in turn
lead to risk modification and smok-
ing cessation as integrated compo-
nents of patient care. Personal risk
calculators are currently available,
but they are not easily accessible to
the public. Such a Web-based tool
might convert a guideline or instruc-
tion into a conversation between
physician and patient, including the
opportunity to further patient interest
in smoking cessation.
Michael T. Jaklitsch, MD
Francine L. Jacobson, MD, MPH
Brigham and Women’s Hospital
Boston, Mass
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j.jtcvs.2012.09.029CORRECTION OF FAULTY
ASSUMPTIONS IN COST-
EFFECTIVENESS ANALYSIS
To the Editor:
We read with interest the Canadian
cost-effectiveness analysis by Doble
and colleagues1 comparing transcath-
eter aortic valve replacement (TAVR)
with standard management (SM) for
inoperable patients and with surgical
aortic valve replacement (SAVR) for
high-risk patients with severe,ardiovascular Surgery c January 2013operable aortic stenosis. Although
we found many aspects of this work
to be well done, we believe that the
published analysis contains a few im-
portant factual errors and a few as-
sumptions that have been
contradicted by recently published
follow-up data from the PARTNER
trial.
First, the Sapien valve (Edwards
Lifesciences LLC, Irvine, Calif)
price in Doble and colleagues’ analy-
sis1 ($37,606) is $13,606 greater
than the current Canadian price of
$24,000 (all figures are in Canadian
dollars). With no other changes to
the model of Doble and colleagues,1
correction of the Sapien valve price
would make TAVR slightly cost sav-
ing (by $2453) relative to SAVR
in high-risk surgical patients and
would reduce the incremental cost-
effectiveness ratio for TAVR relative
to SM from $36,458 to $20,497
per life year gained (or from $51,324
to $29,037 per quality-adjusted life
year gained). Second, Doble and col-
leagues1 estimated the costs of
SAVR in Ontario from provincial
data for patients aged 70 years and
older in Case Mix Group (CMG)
165, cardiac valve repair. SAVR pro-
cedures are not coded under this
CMG in Ontario, however, but rather
under CMG 162 (cardiac valve re-
placement), which has slightly higher
reimbursement. More importantly,
we believe that ‘‘average’’ reimburse-
ment values for SAVR in patients aged
70 years and older are likely to under-
estimate the true costs of SAVR
among patients like those in the
PARTNER trial, whose baseline char-
acteristics in the clinical trial placed
them in the highest 5% to 10% of
predicted operative risk.2
In projecting survival for inopera-
ble patients, Doble and colleagues1
used Canadian life table data for years
2 through 20 of their model for both
TAVR and SM patient cohorts. This
approach assumes that survivals be-
yond 1 year would be similar for the
two groups, in essence ignoring the
